UK AND IRELAND PEPTIDE READINESS · FOUNDING COHORT
One search brings together the regulatory position, the evidence and the route to access for licensed peptide medicines, the late stage pipeline and products patients may already be asking about.
Primary sources where available · MHRA · NICE · AWTTC · SMC · HSC · HPRA · NCPE · HSE · verification dates shown
Independent professional intelligence. No medicine sales. No individual treatment advice. No dosing protocols.
INSTITUTIONAL READINESS
The evidence architecture is being developed with reference to the NICE Evidence Standards Framework. That is a preparation standard, not NICE assessment, endorsement or recommendation.
PEPTIDES FOR TOMORROW'S MEDICINE
Discovery is only the beginning. Researchers, clinicians, pharmacists, regulators and evidence teams must be able to see what is established, what is emerging and where uncertainty remains.
THE CORE ASSET
Government sources answer individual regulatory questions. This view joins the sequence: FDA → MHRA → NICE → NHS access → private context → what comes next.
| Molecule | Current signal | FDA | MHRA | NICE | NHS access | UK readiness | Open |
|---|---|---|---|---|---|---|---|
| SemaglutideGLP-1 receptor agonist peptideSOURCE MAPPED · 6 links | FDA approved comparatorEstablished FDA approved peptide medicine | FDA approved in specific products and indications | UK authorised in specific products and indications | NICE recommendations exist for defined diabetes and obesity uses | NHS access exists within NICE criteria and commissioned pathways | 10 Exposure: Very high | |
| TirzepatideGIP and GLP-1 receptor agonist peptideSOURCE MAPPED · 6 links | FDA approved comparatorEstablished FDA approved dual agonist | FDA approved in specific products and indications | UK authorised in specific products and indications | NICE TA1026 recommends tirzepatide with eligibility criteria | NHS access is phased and prioritised under implementation policy | 10 Exposure: Very high | |
| LiraglutideGLP-1 receptor agonist peptideSOURCE MAPPED · 5 links | FDA approved comparatorEstablished FDA approved peptide medicine | FDA approved in specific products and indications | UK authorised in specific products and indications | NICE TA664 recommends liraglutide for a defined obesity pathway | Specialist NHS access exists within relevant criteria | 10 Exposure: High | |
| TesamorelinGHRH analogue peptideSOURCE MAPPED · 4 links | FDA approved comparatorFDA approved for a narrow specialist indication | FDA approved for a specific US indication | No UK marketing authorisation identified for the US indication | No NICE recommendation identified | No routine NHS access identified | 5 Exposure: High research market | |
| BremelanotideMelanocortin receptor agonist peptideSOURCE MAPPED · 4 links | FDA approved comparatorFDA approved as Vyleesi for a defined indication | FDA approved for a specific US product and indication | No equivalent UK marketing authorisation identified | No NICE recommendation identified | No routine NHS access identified | 4 Exposure: Moderate research market | |
| ElamipretideMitochondrial cardiolipin binding peptideSOURCE MAPPED · 4 links | FDA approved comparatorFDA accelerated approval for Barth syndrome | FDA accelerated approval for a defined rare disease indication | No UK marketing authorisation identified | No NICE recommendation identified | No routine NHS access identified | 4 Exposure: Emerging | |
| SetmelanotideMC4 receptor agonist peptideSOURCE MAPPED · 6 links | FDA approved comparatorFDA approved precision obesity medicine | FDA approved for genetically defined obesity indications | UK authorised for defined genetic obesity indications | NICE highly specialised recommendations exist for defined populations | Highly specialised NHS access exists within NICE criteria | 8 Exposure: Specialist | |
| TeduglutideGLP-2 analogue peptideSOURCE MAPPED · 5 links | FDA approved comparatorFDA approved specialist gastrointestinal peptide | FDA approved for a specific product and indication | UK authorised for a specific product and indication | NICE TA804 recommends teduglutide for short bowel syndrome | Specialist NHS access is subject to NICE criteria and commissioning | 9 Exposure: Specialist | |
| RetatrutideGIP · GLP-1 · glucagon triple agonist peptideSOURCE MAPPED · 5 links | Late stage pipelinePhase 3 programme; sponsor has announced a planned regulatory filing | Investigational; not FDA approved | Investigational; no UK marketing authorisation | No NICE recommendation identified | No routine NHS access | 6 Exposure: Very high grey market interest | |
| CagrilintideLong acting amylin analogue peptideSOURCE MAPPED · 5 links | Late stage pipelinePhase 3 monotherapy programme | Investigational as monotherapy; not FDA approved | Investigational; no UK marketing authorisation | No NICE recommendation identified | No routine NHS access | 5 Exposure: High research market interest | |
| ZenagamtideUnimolecular GLP-1 and amylin receptor agonist peptideSOURCE MAPPED · 5 links | Late stage pipelinePhase 3 obesity programme initiated in 2026 | Investigational; not FDA approved | Investigational; no UK marketing authorisation | No NICE recommendation identified | No routine NHS access | 4 Exposure: Emerging | |
| PemvidutideGLP-1 and glucagon dual receptor agonist peptideSOURCE MAPPED · 5 links | Late stage pipelineGlobal Phase 3 MASH development | Investigational; FDA Breakthrough Therapy designation does not equal approval | Investigational; no UK marketing authorisation | No NICE recommendation identified | No routine NHS access | 4 Exposure: Emerging | |
| SurvodutideGLP-1 and glucagon dual receptor agonist peptideSOURCE MAPPED · 5 links | Late stage pipelineGlobal Phase 3 obesity and MASH programmes | Investigational; not FDA approved | Investigational; no UK marketing authorisation | No NICE recommendation identified | No routine NHS access | 4 Exposure: Emerging | |
| BPC 157Synthetic pentadecapeptideSOURCE MAPPED · 4 links | FDA 2026 compounding reviewFDA PCAC reviewed a 503A bulk substance nomination in July 2026 | Not FDA approved; advisory review is not drug approval | No UK marketing authorisation identified | No NICE recommendation identified | No routine NHS access | 1 Exposure: Very high research market | |
| KPVAlpha MSH derived tripeptideSOURCE MAPPED · 4 links | FDA 2026 compounding reviewFDA PCAC reviewed a 503A bulk substance nomination in July 2026 | Not FDA approved; advisory review is not drug approval | No UK marketing authorisation identified | No NICE recommendation identified | No routine NHS access | 1 Exposure: Growing research market | |
| TB 500Thymosin beta-4-related peptideSOURCE MAPPED · 4 links | FDA 2026 compounding reviewFDA PCAC reviewed a 503A bulk substance nomination in July 2026 | Not FDA approved; advisory review is not drug approval | No UK marketing authorisation identified | No NICE recommendation identified | No routine NHS access | 1 Exposure: Very high research market | |
| MOTS-cMitochondrial derived peptideSOURCE MAPPED · 4 links | FDA 2026 compounding reviewFDA PCAC reviewed 503A bulk substance nominations in July 2026 | Not FDA approved; advisory review is not drug approval | No UK marketing authorisation identified | No NICE recommendation identified | No routine NHS access | 1 Exposure: High research market | |
| Emideltide / DSIPDelta sleep inducing peptideSOURCE MAPPED · 4 links | FDA 2026 compounding reviewFDA PCAC reviewed a 503A bulk substance nomination in July 2026 | Not FDA approved; advisory review is not drug approval | No UK marketing authorisation identified | No NICE recommendation identified | No routine NHS access | 1 Exposure: Moderate research market | |
| SemaxACTH fragment analogue peptideSOURCE MAPPED · 4 links | FDA 2026 compounding reviewFDA PCAC reviewed a 503A bulk substance nomination in July 2026 | Not FDA approved; advisory review is not drug approval | No UK marketing authorisation identified | No NICE recommendation identified | No routine NHS access | 1 Exposure: High nootropic market | |
| EpitalonTetrapeptideSOURCE MAPPED · 4 links | FDA 2026 compounding reviewFDA PCAC reviewed a 503A bulk substance nomination in July 2026 | Not FDA approved; advisory review is not drug approval | No UK marketing authorisation identified | No NICE recommendation identified | No routine NHS access | 1 Exposure: High longevity market | |
| LL-37Human cathelicidin antimicrobial peptideSOURCE MAPPED · 4 links | FDA 2027 compounding reviewListed for forthcoming FDA PCAC consideration | Not FDA approved for marketed wellness uses; committee consideration is not approval | No UK marketing authorisation identified | No NICE recommendation identified | No routine NHS access | 1 Exposure: Emerging | |
| GHK-CuCopper binding tripeptide complexSOURCE MAPPED · 4 links | FDA 2027 compounding reviewListed for forthcoming FDA PCAC consideration | Not FDA approved as an injectable wellness medicine; committee consideration is not approval | No UK injectable marketing authorisation identified for wellness use | No NICE recommendation identified for injectable wellness use | No routine NHS access for this use | 1 Exposure: Very high | |
| Dihexa acetateExperimental peptide derived compoundSOURCE MAPPED · 4 links | FDA 2027 compounding reviewListed for forthcoming FDA PCAC consideration | Not FDA approved; committee consideration is not approval | No UK marketing authorisation identified | No NICE recommendation identified | No routine NHS access | 0 Exposure: Emerging nootropic market | |
| Melanotan IIMelanocortin analogue peptideSOURCE MAPPED · 4 links | FDA 2027 compounding reviewListed for forthcoming FDA PCAC consideration | Not FDA approved; committee consideration is not approval | No UK marketing authorisation identified | No NICE recommendation identified | No routine NHS access | 0 Exposure: Very high grey market | |
| PEG-MGFPegylated mechano-growth factor related peptideSOURCE MAPPED · 4 links | FDA 2027 compounding reviewListed for forthcoming FDA PCAC consideration | Not FDA approved; committee consideration is not approval | No UK marketing authorisation identified | No NICE recommendation identified | No routine NHS access | 0 Exposure: Bodybuilding research market |
Established FDA approved peptide medicine
Established FDA approved dual agonist
Established FDA approved peptide medicine
FDA approved for a narrow specialist indication
FDA approved as Vyleesi for a defined indication
FDA accelerated approval for Barth syndrome
FDA approved precision obesity medicine
FDA approved specialist gastrointestinal peptide
Phase 3 programme; sponsor has announced a planned regulatory filing
Phase 3 monotherapy programme
Phase 3 obesity programme initiated in 2026
Global Phase 3 MASH development
Global Phase 3 obesity and MASH programmes
FDA PCAC reviewed a 503A bulk substance nomination in July 2026
FDA PCAC reviewed a 503A bulk substance nomination in July 2026
FDA PCAC reviewed a 503A bulk substance nomination in July 2026
FDA PCAC reviewed 503A bulk substance nominations in July 2026
FDA PCAC reviewed a 503A bulk substance nomination in July 2026
FDA PCAC reviewed a 503A bulk substance nomination in July 2026
FDA PCAC reviewed a 503A bulk substance nomination in July 2026
Listed for forthcoming FDA PCAC consideration
Listed for forthcoming FDA PCAC consideration
Listed for forthcoming FDA PCAC consideration
Listed for forthcoming FDA PCAC consideration
Listed for forthcoming FDA PCAC consideration
FIRST MARKET SCOPE
The launch model separates authorisation from country specific assessment, reimbursement, commissioning and implementation.
Compare access routes
LAWFUL UK CLINICAL USE NOW
The useful starting point is what can lawfully be prescribed or supplied in the UK now, for which indication, under what governance, and whether NICE and the NHS support access.
GLP-1 peptide
GIP / GLP-1 peptide
GLP-1 peptide
MC4 receptor agonist peptide
GLP-2 analogue peptide
PTHrP analogue peptide
Growth hormone therapeutics
PTH analogue peptide
EXPOSURE SURVEILLANCE
Observed combinations are market and clinic signals, not recommendations. Component evidence does not establish the safety, quality or efficacy of a premixed product.
A common research market pairing. No approved combination product and no controlled combination evidence establishing the marketed use.
High exposure · evidence gapObserved as KLOW style market architecture. Four components compound questions of identity, attribution, stability and sterility.
High complexity · high governance needA frequently described clinic and research pairing. Component rationale is not validation of a fixed premixed formulation.
Established market patternINVITE ONLY BETA · FIRST COHORT
We are inviting a small group of clinicians, pharmacists, governance professionals and life sciences teams to test the platform against real professional questions before wider launch.